FDA ap­proves first sub­cu­ta­neous ver­sion of block­buster IBD drug in­flix­imab

The FDA on Sun­day ap­proved Cell­tri­on’s Zym­fen­tra (in­flix­imab-dyyb), which is the first sub­cu­ta­neous ver­sion of the block­buster bi­o­log­ic, as main­te­nance ther­a­py for in­flam­ma­to­ry bow­el dis­ease.

The ap­proval is based on pos­i­tive da­ta from two Phase III tri­als that as­sessed the ef­fi­ca­cy of Zym­fen­tra as main­te­nance ther­a­py in pa­tients with mod­er­ate to se­vere ul­cer­a­tive col­i­tis and Crohn’s dis­ease. The com­pa­ny said the tri­als demon­strat­ed su­pe­ri­or­i­ty in the pri­ma­ry end­points of clin­i­cal re­mis­sion and en­do­scop­ic re­sponse com­pared to place­bo as main­te­nance ther­a­py af­ter in­duc­tion ther­a­py of in­tra­venous for­mu­la­tion of in­flix­imab in pa­tients with UC and Crohn’s, over a 54-week pe­ri­od.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER